LRRK2p.G2019S Mutation Is Not Common among Alzheimer’s Disease Patients in Brazil

Author:

Santos-Rebouças Cíntia Barros1,Abdalla Cláudia Bueno1,Martins Paloma Águia1,Baldi Fábio José Rodrigues1,Santos Jussara Mendonça1,Motta Luciana Branco2,de Borges Margarete Borges3,Souza Dorotéia Rossi Silva4,de Souza Pinhel Marcela Augusta4,Laks Jerson3,Pimentel Márcia Mattos Gonçalves1

Affiliation:

1. Departamento de Genética, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

2. Núcleo de Atenção ao Idoso, Universidade do Estado do Rio de Janeiro, Brazil

3. Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro, Brazil

4. Departamento de Biologia Molecular, Faculdade de Medicina de São José do Rio Preto, Brazil

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have emerged as a potential common cause for both sporadic and familial Parkinson’s Disease (PD) in different populations. The pleomorphic features exhibited by LRRK2 mutation carriers and the central role of Lrrk2 protein in the proper functioning of central nervous system suggest that mutations in this protein might be involved in multiple cellular processes leading to other neurodegenerative disorders than PD. The location of LRRK2 gene on chromosome 12, close to a linkage peak for familial late-onset Alzheimer’s Disease (AD), highlights that LRRK2 mutations might be involved in AD pathogenesis. We screened the most common LRRK2 mutation (p.G2019S) in a series of 180 consecutive patients clinically diagnosed with Alzheimer Disease (AD). We identified the p.G2019S in one AD patient with no PD signs, indicating that this mutation is not a common etiological factor for AD in our population (0.5%), corroborating recent data found in Norwegian, North American, Chinese and Italian populations. Nevertheless, these observations together with new information about the Lrrk2 critical multifunctionality do not rule out the possible influence of other variants within LRRK2 in AD, so that other screenings focusing in the whole extension of the LRRK2 using larger sized confirmed AD sample are urgently needed.

Funder

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Publisher

Hindawi Limited

Subject

Biochemistry, medical,Clinical Biochemistry,Genetics,Molecular Biology,General Medicine

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3